For the retired neurologist Daniel Gibbs, a diagnosis of early-stage Alzheimer’s not only gave him a sense of relief, but also a clear path…
Following the FDA’s approval of the new Alzheimer’s drug Aduhelm (aducanumab), retired neurologist Daniel Gibbs spoke with Being Patient in a recent LiveTalk about…
The FDA’s approval of Biogen’s new anti-amyloid drug Aduhelm was a landmark moment for Alzheimer’s — and it comes with no small amount of…
Lifestyle changes can lower our dementia risk. Dr. Eric Larson, senior investigator at Kaiser Permanente Washington Health Research Institute, dives into the science to…
Following the FDA’s approval of aducanumab, marketed under the name Aduhelm, an aducanumab trial principal investigator and a former aducanumab trial site investigator speak…
As part of our LiveTalks series, Being Patient spoke with Gail Gregory, Peter Middleton and George Rook about their dementia diagnoses and what it…
The FDA is expected to decide whether or not to approve Biogen and Eisai’s experimental Alzheimer’s drug, aducanumab, in less than a week. Geri…